EX-99.1

•

Completed $5 million share repurchase program; repurchased total of 815,000 shares year-to-date

•

Launched TRUEbalance blood glucose monitoring system and TRUEmanager Diabetes Management Software

FORT LAUDERDALE, Fla. – August 6, 2009 – Home Diagnostics, Inc. (Nasdaq: HDIX), a leading manufacturer and marketer of diabetes testing supplies, today announced financial results for the second quarter ended June 30, 2009.

Total revenue for the second quarter was $32.7 million, a decrease of 2.1% from $33.4 million in the second quarter of 2008. Retail channel sales were up 45.2%, driven by the continued national rollout of the TRUEresult and TRUE2go blood glucose monitoring systems and the expanded product portfolio at Walmart. Mail service channel sales increased 9.7%, driven by the private label, no-coding blood glucose monitoring system recently launched with Liberty Medical and the initial launch of the TRUEbalance no-coding blood glucose system with several customers. Distribution channel sales decreased 17.0% as a result of fewer large stocking orders and the reduction to inventory days supply, as anticipated, at some of the Company’s wholesale distribution customers. International sales decreased 22.3%, reflecting lower sales in Latin America following the Company’s decision to limit its exposure in that region due to poor economic conditions.

Gross profit for the second quarter of 2009 was $17.3 million, compared to $19.9 million in the second quarter of 2008. As a percentage of sales, gross margin decreased to 53.0% compared to 59.6% in the prior year period. As the Company previously guided, gross margin was negatively impacted by the continued investment in the roll out of the new no-code products in the retail and mail service channels. Gross margin was also impacted by lower pricing in the mail service and distribution channels. On a sequential basis, second quarter 2009 gross margin improved 590 basis points from 47.1% in the first quarter 2009 as a result of improved yields on the TRUEtest manufacturing line and increased test strip volume.

Selling, general and administrative expenses were $12.6 million for the second quarter of 2009, compared with $13.7 million in the second quarter of 2008. The decrease in selling, general and administrative expenses is primarily due to lower sales and marketing expenses following the initial launch of the TRUE2go and TRUEresult systems last year and cost reduction initiatives.

Research and development expenses were $2.0 million for the second quarter of 2009, compared with $2.4 million in the second quarter of 2008. The decrease in research and development expenses is primarily due to lower product development costs following the initial launch of the TRUE2go and TRUEresult systems last year.

Operating income for the second quarter of 2009 was $2.8 million, compared to operating income of $3.8 million for the second quarter of 2008.

For the three-month period ended June 30, 2009, the Company reported net income of $1.9 million, or $0.11 per diluted share, based on weighted average shares outstanding of 17.6 million. Net income for the three-month period ended June 30, 2008 was $2.7 million, or $0.14 per diluted share, based on 18.9 million weighted average shares outstanding.

Joseph Capper, President and Chief Executive Officer of Home Diagnostics, said, “Our earnings during the quarter were at the high end of our guidance, driven by yield improvements from our TRUEtest manufacturing line and newly implemented cost reduction initiatives. We are particularly pleased with our domestic sales which grew during the quarter, outpacing the reported results of the majority of our branded competitors, which reported sales declines for the quarter. This reflects our position as a leading provider of value-priced, high-quality blood glucose monitoring products. We achieved 45% growth in our retail channel, driven by strong reception of our new products, TRUEresult and TRUE2go, as well as organic growth of existing products with our major retail partners.”

2009 Financial Guidance
The Company is updating its full year 2009 guidance of revenue to now be in the range of $129 million to $131 million and diluted earnings per share to be in the range of $0.36 to $0.38 from the previous estimate of $130 million to $133 million and diluted earnings per share in the range of $0.36 to $0.40. The Company anticipates that second half 2009 revenue and earnings will be more heavily weighted towards the fourth quarter due to the timing of purchases in the distribution channel and the ramp up of new product launches.

Conference Call
Home Diagnostics will hold a conference call on Thursday, August 6, 2009 at 8:30 a.m. ET to discuss its operating results. The dial-in numbers are 1-877-407-0789 for domestic callers and 1-201-689-8562 for international callers. A live Webcast of the conference call will be available online from the investor relations page of the Company’s corporate Website at www.homediagnostics.com.

After the live Webcast, the call will remain available on Home Diagnostics’ Website, www.homediagnostics.com, through September 6, 2009. In addition, a telephonic replay of the call will be available until August 13, 2009. The replay dial-in numbers are 1-877-660-6853 for domestic callers and 1-201-612-7415 for international callers. Please use account number 3055 and conference ID number 327813.

Based in Fort Lauderdale, Florida, Home Diagnostics, Inc. (NASDAQ: HDIX) is a leading developer, manufacturer and marketer of diabetes management products. Home Diagnostics, Inc. offers a portfolio of high-quality blood glucose monitoring systems that spans the spectrum of features and benefits to help every person with diabetes better monitor and manage their disease. The Home Diagnostics, Inc. product line includes TRUE2go™, TRUEresult™, TRUEbalance™, TRUEtrack®, Sidekick®, TRUEread™ and Prestige Smart System® blood glucose monitoring systems. The products are available in more than 45,000 pharmacies throughout the U.S. Home Diagnostics is the exclusive co-brand supplier of blood glucose monitoring supplies for leading pharmacies including CVS, Rite Aid and Walgreens, as well as distributors such as AmerisourceBergen, Cardinal Health, McKesson, Invacare and Liberty Medical. Home Diagnostics, Inc. was named one of Forbes magazine’s “200 Best Small Companies” in 2008, and in 2009 received several recognitions for the company’s TRUE2go blood glucose meter, including a Medical Design Excellence Award (MDEA) and a Gold Award in the Medical/Test Equipment category as part of appliance DESIGN Magazine’s 22nd Annual Excellence in Design (EID) Awards Competition. For more information please visit www.homediagnostics.com.

All statements other than statements of historical facts included in this release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These forward-looking statements are largely based on our expectations and beliefs concerning future events, which reflect estimates and assumptions made by the Company’s management. These estimates and assumptions reflect the Company’s best judgment based on currently known market conditions and other factors relating to the Company’s operations and business environment, all of which are difficult to predict and many of which are beyond its control. Although the Company believes its estimates and assumptions to be reasonable, they are inherently uncertain and involve a number of risks and uncertainties that are beyond the Company’s control. In addition, management’s assumptions about future events may prove to be inaccurate. Management cautions all readers that the forward-looking statements contained in this release are not guarantees of future performance, and the Company cannot assure any reader that those statements will be realized or the forward-looking events and circumstances will occur. Actual results may differ materially from those anticipated or implied in the forward-looking statements due to the factors listed in the “Risk factors” and “Management’s discussion and analysis of financial condition and results of operations” sections contained in its filings with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this release. The Company does not intend to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise, except as required by law. These cautionary statements qualify all forward-looking statements attributable to the Company or persons acting on its behalf.

TRUE2go, TRUEresult, TRUEtest, TRUEtrack, TRUEbalance, Sidekick, TRUEread, Prestige Smart System and TRUEmanager are trademarks of Home Diagnostics, Inc. All other trademarks are property of their respective owners.

HOME DIAGNOSTICS, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
(Unaudited)


	Three Months Ended										Six Months Ended
	June 30,										June 30,
	2008		% to Sales			2009		% to Sales			2008			% to Sales			2009		% to Sales
Net sales	$	33,355,841		100.0	%	$	32,653,785		100.0	%	$	58,476,121			100.0	%	$	57,255,413		100.0	%
Cost of sales		13,469,076		40.4	%		15,338,500		47.0	%		24,001,009			41.0	%		28,356,894		49.5	%

Gross profit		19,886,765		59.6	%		17,315,285		53.0	%		34,475,112			59.0	%		28,898,519		50.5	%

Operating expenses:
Selling, general and administrative (including stock-based compensation expense of $510,325 and $439,409 and $743,326 and $745,998 for the three and six months ended June 30, 2008 and 2009,respectively)		13,698,713		41.0	%		12,574,343		38.5	%		25,569,431			43.8	%		24,683,190		43.1	%
Research & Development		2,426,666		7.3	%		1,971,113		6.0	%		4,783,514			8.2	%		3,854,716		6.7	%

Total operating expenses		16,125,379		48.3	%		14,545,456		44.5	%		30,352,945			52.0	%		28,537,906		49.8	%

Income from operations		3,761,386		11.3	%		2,769,829		8.5	%		4,122,167			7.0	%		360,613		0.6	%

Other income (expense):
Interest income (expense), net		213,719		0.6	%		15,558		0.0	%		541,587			0.9	%		65,706		0.1	%
Other income (expense), net		105,992		0.3	%		17,866		0.1	%		(420,589	)		-0.7	%		137,671		0.3	%

Other, net		319,711		0.9	%		33,424		0.1	%		120,998			0.2	%		203,377		0.4	%

Income before provision for income taxes		4,081,097		12.2	%		2,803,253		8.6	%		4,243,165			7.2	%		563,990		1.0	%
Provision for income taxes		1,396,838		4.2	%		907,494		2.8	%		837,540			1.4	%	$	367,230		0.6	%

Net income	$	2,684,259		8.0	%	$	1,895,759		5.8	%	$	3,405,625			5.8	%	$	196,760		0.4	%

Earnings per common share:
Basic	$	0.15				$	0.11				$	0.19					$	0.01

Diluted	$	0.14				$	0.11				$	0.18					$	0.01

Weighted average shares used in computing earnings per common share:
Basic		17,841,219					16,876,361					17,869,996						17,099,945

Diluted		18,917,812					17,619,996					18,957,332						17,846,953


	Three Months Ended June 30,						Six Months Ended June 30,
	2008			2009			2008			2009
Cash Flow Data:
Cash provided by operating activities	$	5,305,754		$	2,701,154		$	6,215,547		$	1,478,709
Cash used in investing activities		(1,595,846	)		(3,102,576	)		(3,322,207	)		(7,721,847	)
Cash provided by (used in) financing activities		(1,423,826	)		(1,536,319	)		(1,442,266	)		(4,261,527	)


Revenue by Channel:	Three Months Ended June 30,
	2008				2009				Increase (Decrease)
Domestic:
Retail	$	6,077,281	18.2	%	$	8,826,815	27.0	%	$	2,749,534		45.2	%
Distribution		17,884,002	53.6	%		14,849,964	45.5	%		(3,034,038	)	-17.0	%
Mail Service		5,254,149	15.8	%		5,761,221	17.6	%		507,072		9.7	%

Total Domestic		29,215,432	87.6	%		29,438,000	90.1	%		222,568		0.8	%
International		4,140,409	12.4	%		3,215,785	9.9	%		(924,624	)	-22.3	%

Total	$	33,355,841	100.0	%	$	32,653,785	100.0	%	$	(702,056	)	-2.1	%


Revenue By Channel:	Six Months Ended June 30,
	2008				2009				Increase (Decrease)
Domestic
Retail	$	12,555,199	21.5	%	$	16,940,375	29.6	%	$	4,385,176		34.9	%
Distribution		29,207,299	49.9	%		24,025,561	42.0	%		(5,181,738	)	-17.7	%
Mail Service		9,590,904	16.4	%		11,044,957	19.3	%		1,454,053		15.2	%

Total Domestic		51,353,402	87.8	%		52,010,893	90.9	%		657,491		1.3	%
International		7,122,719	12.2	%		5,244,520	9.1	%		(1,878,199	)	-26.4	%

Total	$	58,476,121	100.0	%	$	57,255,413	100.0	%	$	(1,220,708	)	-2.1	%


	December 31,		June 30,
	2008		2009
Selected Balance Sheet Data:
Cash and cash equivalents	$	30,366,785	$	20,001,006
Working capital		44,005,456		37,416,503
Total assets		141,339,701		140,869,252
Total stockholders’ equity		112,065,961		108,860,059


*Home Diagnostics* Ronald L. Rubin Chief Financial Officer (954) 332-2128 Sabrina Rios Corporate Communications Manager (954) 332-2141 srios@hdidiabetes.com		*The Ruth Group* Nick Laudico (646) 536-7030 nlaudico@theruthgroup.com